'Windlas Biotech Limited Reports its Q4 and FY26 Financial Results'
WINDLAS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Windlas Biotech reported its 13th consecutive quarter of record revenue with Q4FY26 revenue at Rs 238 Cr (18% YoY). Full year FY26 revenue reached Rs 904 Cr, up 19% YoY, crossing the Rs 900 Cr milestone for the first time. Adjusted EBITDA grew 26% to Rs 121 Cr with margins at 13.4%, while Adjusted PAT rose 31% to Rs 83 Cr with margins at 9.2%. The CDMO vertical contributed 73% of revenue at Rs 664 Cr (20% YoY). The company maintains strong balance sheet with Rs 251 Cr net liquidity and is net debt free. Plant-6 has achieved mechanical completion and is on track for commercialization by H1 FY27. A Rs 47 Cr buyback was completed without promoter participation, and dividend of Rs 13 Cr (Rs 6.30 per share) has been proposed.
Strong operational performance with margin expansion and cash generation positions the company well for continued growth. The net debt-free status and Rs 251 Cr liquidity provide financial flexibility for expansion. The upcoming Plant-6 commercialization and growing CDMO business support future revenue visibility.